Lemonade Inc vs McKesson Corporation — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 29.9× Lemonade Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and McKesson Corporation for 74 Days on average.
| LMND | MCK | |
|---|---|---|
Market Cap | $3.63B | $108.46B |
Volume | 1,544,794 | 712,607 |
Sector | Financials | Health |
52-Week High | $96.57 | $995.69 |
52-Week Low | $43.91 | $725.17 |
Typical Hold Time | 27 Days | 74 Days |
Enterprise Value | $3.49B | $115.00B |
Dividend Yield | — | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $46.91, up 0.17% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $738 million, and net losses narrowing to -$166 million. Recent news highlights expansion into new states and AI-driven efficiency gains, with management targeting EBITDA profitability by late 2026.
The outlook is mixed: growth and margin improvement offer upside, but persistent losses and high valuation multiples pose risks. Analysts are divided with a consensus price target of $67, suggesting potential upside if profitability targets are met. Key risks include execution on profitability and competitive pressures in the insurtech space.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →